earnings
confidence high
sentiment negative
materiality 0.85
Prestige Q1 revenue down 6.6%, misses; acquires Pillar5 for CAD 150M, cuts FY26 outlook
Prestige Consumer Healthcare Inc.
2026-Q1 EPS
reported $0.95
vs consensus $1.40
▼ miss
(-32.3%)
- Revenue $249.5M (-6.6% YoY); diluted EPS $0.95 ($0.90 adjusted).
- Clear Eyes supply constraints drove North American OTC revenue down to $212.6M.
- Acquiring Pillar5 Pharma for CAD 150M cash; expected to close Q3 FY2026.
- FY2026 outlook cut: revenue now $1.10-1.115B, EPS $4.50-4.58 (from $4.70-4.82).
- Net debt ~$0.9B; leverage 2.4x; free cash flow guidance unchanged at $245M+.